Real-world evidence research in metastatic colorectal cancer: raising awareness of the need for patient contributions.
Barbara MossEdward A GoodallZorana MaravicFrancisca MartiMark MossStephen RowleyCyril SarraustePete WheatstonePublished in: Future oncology (London, England) (2023)
Real-world evidence (RWE) research helps determine whether outcomes observed in clinical trials happen in real-life clinical practice. RWE research may help patients receive more appropriate treatment, closer to their needs and wishes. RWE for metastatic colorectal cancer (mCRC) is currently limited. The PROMETCO RWE study is an important example of an ongoing initiative that focuses on patient-reported outcomes in mCRC. Patients play an active role throughout the RWE research process, including study design, participation and results dissemination. This involvement can encourage greater patient empowerment through active engagement, potentially resulting in various benefits that can lead to improved clinical outcomes. Greater patient engagement can increase involvement in RWE, helping more patients to access the benefits of RWE research.
Keyphrases
- patient reported outcomes
- end stage renal disease
- ejection fraction
- newly diagnosed
- metastatic colorectal cancer
- chronic kidney disease
- clinical trial
- prognostic factors
- clinical practice
- peritoneal dialysis
- randomized controlled trial
- physical activity
- type diabetes
- adipose tissue
- insulin resistance
- open label
- phase ii